Petros Pharmaceuticals, Inc. Cash and Cash Equivalents, Fair Value Disclosure
Petros Pharmaceuticals, Inc. (PTPI) had Cash and Cash Equivalents, Fair Value Disclosure of $3.30 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-08-13
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $3.30M.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $4.30M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $4.70M.
- 2025-09-30: Cash and Cash Equivalents, Fair Value Disclosure $6.10M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $3.30M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $4.30M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $4.70M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $6.10M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $6.60M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $8.90M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.00M 10-K · filed 2026-04-15 |
| 2023-12-31 | $10.40M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |